So far, FDA have approved four CD19-targeted CAR-T cell products for refractory B cell malignancies, and two B cell maturation antigen (BCMA)-targeted CAR-T cell products for multiple myeloma (MM), which are provided for patients who relapse at least after four prior lines of treatment [3, 4]. This evidence concerns the gene TNFRSF17 and AL amyloidosis.